The Purpose of This Study is to Compare the Therapy Effects and Clinical Safety of a Regulatory Metabolic Compound, Coenzyme A (CoA) With a Marketed Drug, Abiraterone, in Chinese Patients With Castration-resistant Prostate Cancer (CRPC) .

The purpose of this study is to compare the therapy effects and clinical safety of a regulatory metabolic compound, coenzyme A (CoA) with a marketed drug, abiraterone, in Chinese patients with castration-resistant prostate cancer (CRPC) .

Start Date18 Mar 2021

Sponsor / Collaborator

Jiangnan University

[+1]

NCT01928342

/ Unknown statusPhase 2/3IIT

The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia: a Randomized, Double-blinded, Placebo-controlled, Multi-center Clinical Trial

The purpose of this study is to evaluate the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A （CoA） capsule, combined use with statin, in Chinese patients with moderate dyslipidemia.

Start Date01 Mar 2012

Sponsor / Collaborator

Zhejiang University

NCT01878227

/ CompletedPhase 3IIT

Randomized Head-to-Head Comparison of Coenzyme A Capsule and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia: A Phase III, Multicenter, Double-blinded, Double Dummy Clinical Trial.

The purpose of this study is to compare the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A capsule with a marketed drug, fenofibrate, in Chinese patients with moderate dyslipidemia.

Start Date01 Jul 2010

Sponsor / Collaborator

Zhejiang University

100 Clinical Results associated with Coenzyme A(Chengdu Tongde Pharmaceutical)

100 Translational Medicine associated with Coenzyme A(Chengdu Tongde Pharmaceutical)

100 Patents (Medical) associated with Coenzyme A(Chengdu Tongde Pharmaceutical)

335

Literatures (Medical) associated with Coenzyme A(Chengdu Tongde Pharmaceutical)

12 Mar 2025·Journal of Agricultural and Food Chemistry

Efficient Synthesis of Vitamin B₅ in Escherichia coli by Engineering Ketopantoate Hydroxymethyltransferase and Cofactor Supply

Article

Author: Zhang, Heng ; Xu, Sha ; Yin, Xinran ; Wang, Ke ; Song, Fuqiang ; Qin, Zhijie ; Zhou, Jingwen ; Qiu, Kun

d-pantothenic acid (d-PA), also known as vitamin B₅, is an essential precursor of coenzyme A and plays a crucial role in maintaining the physiological functions of organisms. Ketopantoate hydroxymethyltransferase (PanB), encoded by panB gene, serves as a key rate-limiting enzyme in d-PA synthesis. Additionally, the catalytic function of PanB requires the cofactor 5,10-methylenetetrahydrofolate (5,10-CH₂-THF). This study aimed to increase d-PA production by engineering ketopantoate hydroxymethyltransferase and cofactor supply. The key transcription factor bhsA that restricts d-PA production was screened and identified through transcription factor engineering applications. Subsequently, PanB was coexpressed with PanC to regulate expression. Furthermore, the highly catalytic mutant PanBM^V123I/K124W was generated through Km/Kcat algorithm prediction and enzyme engineering, leading to a 2.5-fold increase in d-PA production. The de novo synthesis pathway of 5,10-CH₂-THF was enhanced, whereas its degradation pathway was suppressed to improve cofactor supply. Then, the extracellular transport of d-PA was enhanced by introducing the d-PA transporter PanT from Streptococcus intermedius. The plasmid-free strain DPA23 produced 78.48 g/L of d-PA in a 5-L bioreactor, with a productivity of 2.69 g/L/h after 24 h and a glucose yield of 0.54 g/g. These strategies provided a reference for constructing microbial cell factories for d-PA and its derivatives.

16 Oct 2024·mBio

Coenzyme A biosynthesis in Bacillus subtilis : discovery of a novel precursor metabolite for salvage and its uptake system

Article

Author: Klein, Moritz ; Warneke, Robert ; Herzberg, Christina ; Feussner, Kirstin ; Stülke, Jörg ; Dittmann, Josi ; Elfmann, Christoph ; Feussner, Ivo

ABSTRACT The Gram-positive model bacterium Bacillus subtilis is used for many biotechnological applications, including the large-scale production of vitamins. For vitamin B5, a precursor for coenzyme A synthesis, there is so far no established fermentation process available, and the metabolic pathways that involve this vitamin are only partially understood. In this study, we have elucidated the complete pathways for the biosynthesis of pantothenate and coenzyme A in B. subtilis . Pantothenate can not only be synthesized but also be taken up from the medium. We have identified the enzymes and the transporter involved in the pantothenate biosynthesis and uptake. High-affinity vitamin B5 uptake in B. subtilis requires an ATP-driven energy coupling factor transporter with PanU (previously YhfU) as the substrate-specific subunit. Moreover, we have identified a salvage pathway for coenzyme A acquisition that acts on complex medium even in the absence of pantothenate synthesis. This pathway requires rewiring of sulfur metabolism resulting in the increased expression of a cysteine transporter. In the salvage pathway, the bacteria import cysteinopantetheine, a novel naturally occurring metabolite, using the cystine transport system TcyJKLMN. This work lays the foundation for the development of effective processes for vitamin B5 and coenzyme A production using B. subtilis . IMPORTANCE Vitamins are essential components of the diet of animals and humans. Vitamins are thus important targets for biotechnological production. While efficient fermentation processes have been developed for several vitamins, this is not the case for vitamin B5 (pantothenate), the precursor of coenzyme A. We have elucidated the complete pathway for coenzyme A biosynthesis in the biotechnological workhorse Bacillus subtilis . Moreover, a salvage pathway for coenzyme A synthesis was found in this study. Normally, this pathway depends on pantetheine; however, we observed activity of the salvage pathway on complex medium in mutants lacking the pantothenate biosynthesis pathway even in the absence of supplemented pantetheine. This required rewiring of metabolism by expressing a cystine transporter due to acquisition of mutations affecting the regulation of cysteine metabolism. This shows how the hidden “underground metabolism” can give rise to the rapid formation of novel metabolic pathways.

01 Sep 2024·Journal of Inherited Metabolic Disease

Impaired coenzyme A homeostasis in cardiac dysfunction and benefits of boosting coenzyme A production with vitamin B5 and its derivatives in the management of heart failure

Review

Author: Wedman, J. J. ; Iuso, A. ; Sibon, O. C. M. ; Mastantuono, E.

AbstractCoenzyme A (CoA) is an essential cofactor required for over a hundred metabolic reactions in the human body. This cofactor is synthesized de novo in our cells from vitamin B5, also known as pantothenic acid, a water‐soluble vitamin abundantly present in vegetables and animal‐based foods. Neurodegenerative disorders, cancer, and infectious diseases have been linked to defects in de novo CoA biosynthesis or reduced levels of this coenzyme. There is now accumulating evidence that CoA limitation is a critical pathomechanism in cardiac dysfunction too. In the current review, we will summarize our current knowledge on CoA and heart failure, with emphasis on two primary cardiomyopathies, phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency disorders biochemically characterized by a decreased level of CoA in patients' samples. Hence, we will discuss the potential benefits of CoA restoration in these diseases and, more generally, in heart failure, by vitamin B5 and its derivatives pantethine and 4′‐phosphopantetheine.

100 Deals associated with Coenzyme A(Chengdu Tongde Pharmaceutical)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Leukopenia	China	Chengdu Tongde Pharmaceutical Co. Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis